Compare · BLCO vs LUCY
BLCO vs LUCY
Side-by-side comparison of Bausch + Lomb Corporation (BLCO) and Innovative Eyewear Inc. (LUCY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BLCO and LUCY operate in Ophthalmic Goods (Health Care), so they compete in similar markets.
- BLCO is the larger of the two at $5.95B, about 810.7x LUCY ($7.3M).
- Both names hit the wire about 6 times in the past 4 weeks.
- BLCO has more recent analyst coverage (21 ratings vs 0 for LUCY).
- Company
- Bausch + Lomb Corporation
- Innovative Eyewear Inc.
- Price
- -
- -
- Market cap
- $5.95B
- $7.3M
- 1M return
- -1.79%
- -
- 1Y return
- +9.79%
- -
- Industry
- Ophthalmic Goods
- Ophthalmic Goods
- Exchange
- NYSE
- NASDAQ
- IPO
- 2022
- 2022
- News (4w)
- 6
- 6
- Recent ratings
- 21
- 0
Bausch + Lomb Corporation
Bausch + Lomb Corporation operates as an eye health company in Canada and internationally. It operates through three segments: Vision Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that cover the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment glaucoma, ocular hypertension, and retinal diseases; and contact lenses for therapeutic use. The Surgical segment provides tools and technologies for the treatment of cataracts, and vitreous and retinal eye conditions. It offers intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices. The company was founded in 1853 and is headquartered in Vaughan, Canada.
Latest BLCO
- SEC Form 8-K filed by Bausch + Lomb Corporation
- Bausch + Lomb and Bausch Health Announce Appointment of Thomas J. Appio as Interim Bausch + Lomb CEO, Expect to Raise Full-Year 2026 Guidance
- Barclays initiated coverage on Bausch + Lomb with a new price target
- Bausch + Lomb Advances Novel Oral Treatment for Dry AMD Following Constructive FDA Meeting
- Bausch + Lomb Will Release Third-Quarter 2026 Financial Results on Oct. 28
- SEC Form 144 filed by Bausch + Lomb Corporation
- Bausch + Lomb Announces European CE Mark Approval of SeeLyra™ Femtosecond Laser
- Leerink Partners initiated coverage on Bausch + Lomb with a new price target
- Bausch + Lomb Announces New Published Research on enVista Aspire™ Real World Experience
- Most Women Don't Recognize Dry Eye as a Symptom of Perimenopause and Menopause, New Bausch + Lomb Survey Finds
Latest LUCY
- SEC Form 8-K filed by Innovative Eyewear Inc.
- SEC Form 8-K filed by Innovative Eyewear Inc.
- Innovative Eyewear, Inc. Launches Lucyd Aero
- Innovative Eyewear Reports Record Preliminary Q3 2026 Net Sales, Up 55% Year-Over-Year
- SEC Form DEF 14A filed by Innovative Eyewear Inc.
- SEC Form PRE 14A filed by Innovative Eyewear Inc.
- Innovative Eyewear, Inc. Announces Exclusive Australia and New Zealand Distribution Partnership with Directed Electronics
- Innovative Eyewear, Inc. Announces Q3 Business Update
- Chief Financial Officer Gayle Oswald was granted 32,466 shares and sold $13,491 worth of shares (15,533 units at $0.87), increasing direct ownership by 591% to 19,798 units (SEC Form 4)
- Chief AI & Growth Officer Dabrowski Konrad sold $11,874 worth of shares (13,627 units at $0.87) and was granted 41,800 shares, increasing direct ownership by 220% to 40,977 units (SEC Form 4)